ArticleJournal of Zhejiang University. Science. B2015
Morphological and physiological comparison of taxa comprising the Sporothrix schenckii complex.
Article in Journal of Zhejiang University. Science. B, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- What are the 100 most cited fungal genera?Studies in mycology · 2024Article
- Sporotrichosis Outbreak Due toJournal of fungi (Basel, Switzerland) · 2023Article
- Sporotrichosis: A Review of a Neglected Disease in the Last 50 Years in Brazil.Microorganisms · 2022Review
- Current Progress on Epidemiology, Diagnosis, and Treatment of Sporotrichosis and Their Future Trends.Journal of fungi (Basel, Switzerland) · 2022Review
- Important Mycosis of Wildlife: Emphasis on Etiology, Epidemiology, Diagnosis, and Pathology-A Review: PART 2.Animals : an open access journal from MDPI · 2022Review
- The threat of emerging and re-emerging pathogenic Sporothrix species.Mycopathologia · 2020Review
- Epidemiology of fungal infections in China.Frontiers of medicine · 2018Review
- Genetic variation of Sporothrix globosa isolates from diverse geographic and clinical origins in China.Emerging microbes & infections · 2017Article
- Whole-Genome Sequencing and In Silico Analysis of Two Strains of Sporothrix globosa.Genome biology and evolution · 2016Article
- Sporotrichosis: an update on epidemiology, etiopathogenesis, laboratory and clinical therapeutics.Anais brasileiros de dermatologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Based on recent molecular data, it has been suggested that Sporothrix globosa is the main causal agent of sporotrichosis in China. The objective of this study was to compare the morphology, growth characteristics, patterns of carbon source usage, and susceptibility to antifungal agents among Sporothrix strains. A total of 15 clinical strains confirmed to be S. globosa, from three different regions of China, and 11 ex-type strains from the CBS-KNAW biodiversity center were obtained. The elongated conidia of S. pallida, S. variecibatus, S. schenckii, and S. schenckii luriei were clearly different from the subglobose and globose conidia of S. globosa strains. S. schenckii is able to assimilate sucrose, raffinose, and ribitol. Susceptibility profiles of these Sporothrix species were evaluated by measuring minimum inhibitory concentrations (MICs). Fluconazole, itraconazole, terbinafine, and amphotericin B showed good activity against most S. globosa clinical isolates from China. Potassium iodide also showed a low MIC against S. pallida, while fluconazole showed a high MIC for S. mexicana, S. humicola, S. globosa, S. schenckii, and S. inflata; these strains might be considered tolerant. The species showed differences in susceptibility to antifungal drugs and should therefore be properly identified during diagnosis prior to designing therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.